

**CORRIGENDUM**

DOI: 10.3892/or.2022.8411

**TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma**SONG YE, XIN-YI ZHAO, XIAO-GE HU, TANG LI, QIU-RAN XU,  
HUAN-MING YANG, DONG-SHENG HUANG and LIU YANG

Oncol Rep 37: 2215-2226, 2017; DOI: 10.3892/or.2017.5494

Subsequently to the publication of the above article, the authors have realized that a couple of clerical errors were made when writing the article, and wish to correct these errors in a corrigendum statement. First, in the Materials and methods section on p. 2216, the final sentence of the 'Immunohistochemistry and tissue microarray' subsection, the authors wish to add a further definition, so that the text reads as follows (changes highlighted in bold): '**The positive expression of RET was defined as  $\geq 5\%$  staining of a tumor section;** high expression was defined as  $\geq 40\%$  staining of a tumor section, and low expression as  $< 40\%$ '. Secondly, in the Results section, 'Mutation frequency of each gene distributed in 4 biological categories' subsection, p. 2220, right-hand column, second paragraph, line 17, the sentence written here should have read as follows: 'The group with the **positive** expression of RET included 28.9% (26/90) of the patients, **and 4 of these patients were defined as high expression**'.

The authors are grateful to the Editor of *Oncology Reports* for allowing them this opportunity to publish a corrigendum, and apologize to the readership of the journal for any inconvenience caused.



This work is licensed under a Creative Commons  
Attribution 4.0 International (CC BY 4.0) License.